Kirk Charles Johnson alias Dr. TRT Chiro
dispensing certainty at Johnson Chiropractic & Acupuncture P.A.
Website · drkirkjohnson.com
Practice location
825-2511 16104
Foster Street Overland Park, KS 66085
Funnel-first framing that runs on persuasion, light on published evidence.
Oh, look at Kirk Johnson, the 'Chiropractor to lead you on your path to wellness'! He's so bold, offering 'Functional Healthcare' and 'TRT' (Testosterone Replacement Therapy) to the whole family, even though his license only covers spine adjustments. He's name-dropping Cleveland Clinic and Mayo Clinic to validate his shockwave therapy for urology and aesthetics, pretending a DC can do what an MD/DO does. What a genius grift: a chiropractor acting like a doctor, monetizing patients who want systemic disease management without the MD/DO license. Truly, the 'TRT Chiro' is the king of credential inflation.
High grift signals
Score breakdown
Direct answer
Kirk Charles Johnson is licensed in Kansas as a chiropractor (DC), not as an MD or DO, and Kansas's chiropractic scope statute (Kansas chiropractic scope excludes prescription of medicine; Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.) limits that license to musculoskeletal care, not the diagnosis or treatment of systemic disease. Even so, they advertise diagnosing or treating TRT (Testosterone Replacement Therapy), Functional Healthcare, TRT, and Softwave, conditions that belong with endocrinologists.
Key findings
- False Authority: A chiropractor (DC) is framed as the leader of 'functional healthcare' and 'wellness' for all ages, implying broad medical authority that exceeds their state-board license limited to musculoskeletal/spine care.see section ↓
- Claim "Functional Healthcare": not supported by peer-reviewed evidence.see section ↓
- Claim "TRT": mixed in the medical literature.see section ↓
- NPI registry confirms Kirk Johnson as Chiropractor (DC) in Kansas (NPI 1316969751).see section ↓
- Kirk Charles Johnson shows credential inflation relative to stated vs likely credentials.see section ↓
- Dr Kirk Charles Johnson is marketed with a doctor title, but reviewed credentials indicate Chiropractor (DC) rather than an MD/DO physician license.see section ↓
- Against Kansas State Board of Healing Arts (Chiropractic) scope rules (Kansas chiropractic scope excludes prescription of medicine; Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.), these advertised activities appear outside Kirk Charles Johnson's license (including conditions they merely…see section ↓
- 6 of 8 advertised activities fall outside permitted Chiropractor scope in KS.see section ↓
Claims & evidence
8 advertised conditions or treatments fall outside their license scope. Each box leads with state-board scope notation; literature cross-check follows when we matched a specific claim. Every card carries its receipts: the quoted wording, a live source link, and an archived copy.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Prescribing Testosterone Replacement Therapy (TRT), a hormone/endocrine treatment that requires an MD/DO license, not a DC..
Prescribing Testosterone Replacement Therapy (TRT), a hormone/endocrine treatment that requires an MD/DO license, not a DC.
- Supports
- High-quality evidence supports that properly indicated testosterone replacement therapy (TRT) in men with documented hypogonadism can improve several clinical outcomes, particularly sexual function, body composition, and aspects of quality of life. [5][7] Randomized controlled trials show that TRT increases lean body mass and reduces fat mass in hypogonadal men, including those with opioid-induced hypogonadism and aging men, with associated improvements in muscle function and oxidative stress profiles. [6][8] Multiple RCTs and meta-analyses demonstrate that TRT improves sexual function and overall quality of life in hypogonadal patient subgroups, especially men with late-onset hypogonadism and erectile dysfunction, and that exercise can augment and prolong these benefits after discontinuation of TRT. Large cardiovascular safety trials and pooled RCT data indicate that, in men with hypogonadism and preexisting or high cardiovascular risk, TRT does not increase short- to medium-term risk of major adverse cardiovascular events, stroke, myocardial infarction, or all-cause mortality, and shows noninferiority to placebo for major cardiac outcomes when dosed to physiologic levels. [4] Recent meta-analyses of randomized trials and prospective cohorts suggest that when TRT is correctly applied to men with confirmed testosterone deficiency, it is not associated with increased cardiovascular risk and may even be associated with reduced major adverse cardiovascular events and improvements in cardiometabolic risk markers in certain high-risk subgroups. Overall, guideline-based use of TRT in symptomatic men with consistently low testosterone is supported by RCTs, meta-analyses, and major endocrine clinical practice guidelines as an evidence-based therapy to alleviate hypogonadal symptoms, improve sexual function and body composition, and maintain cardiovascular safety in the short to medium term when appropriately monitored. [1][2][3]
- Contradicts
- Evidence contradicts any blanket or unqualified claim that TRT is universally safe, risk-free, or beneficial for all men regardless of indication, dosing, or comorbidities. Meta-analyses of RCTs reveal conflicting findings regarding cardiovascular risk: some earlier pooled analyses reported an increased rate of cardiovascular-related events with testosterone therapy, while others found no clear effect (beneficial or harmful), highlighting uncertainty and the need for adequately powered long-term trials. [5][6][7][8] More recent systematic reviews emphasize that the overall quality of evidence for cardiovascular outcomes has often been low, with bias, inconsistency, and imprecision, and that existing trials were not primarily designed or powered to assess cardiovascular events or long-term mortality. RCT data also show that TRT can raise office blood pressure and is associated with hematocrit increases, with amplified blood pressure responses in men who are obese or have higher baseline red blood cell levels, which challenges any claim that TRT has no hemodynamic downsides. Safety reviews note increased rates of edema and modest reductions in HDL cholesterol in some populations, and guidelines stress that long-term safety beyond the short-to-medium term remains insufficiently characterized, particularly in older men with multiple comorbidities. [2] Therefore, strong claims that TRT prevents cardiovascular disease, is entirely free of cardiovascular or thromboembolic risk, or should be used broadly in men without clear hypogonadism are not supported; the evidence is mixed, context-dependent, and limited for long-term outcomes.
- Mainstream view
- The mainstream medical position is that testosterone replacement therapy is an established treatment for men with confirmed hypogonadism who have consistent biochemical testosterone deficiency and clinically significant symptoms, and should be used in accordance with major endocrine and urology guidelines. [2][5][6][7][8] Routine TRT in men with normal or age-related borderline testosterone levels, without clear symptoms and diagnostic confirmation, is not recommended. When TRT is prescribed, clinicians aim to restore testosterone to the physiological range and monitor hematocrit, lipids, blood pressure, prostate-related parameters, and cardiovascular status. [4] Current evidence indicates that appropriately dosed TRT improves sexual function, mood and energy in some men, and body composition, while short- to medium-term data do not show an increased rate of major cardiovascular events compared with placebo. However, due to prior conflicting meta-analyses, limitations of existing trials, and paucity of long-term safety data, mainstream guidelines consider cardiovascular safety not fully resolved and recommend caution and individualized risk–benefit assessment, especially in older men and those with significant cardiovascular disease. Overall, TRT is viewed as a useful, evidence-based therapy for properly selected hypogonadal men under medical supervision, not as a general longevity or performance drug for the broader male population. [1]
“TRT”
Rule: Kansas chiropractic scope excludes prescription of medicine; Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure TRT (Testosterone Replacement Therapy).
TRT (Testosterone Replacement Therapy)
- Supports
- High-quality evidence supports that properly indicated testosterone replacement therapy (TRT) in men with documented hypogonadism can improve several clinical outcomes, particularly sexual function, body composition, and aspects of quality of life. [5][7] Randomized controlled trials show that TRT increases lean body mass and reduces fat mass in hypogonadal men, including those with opioid-induced hypogonadism and aging men, with associated improvements in muscle function and oxidative stress profiles. [6][8] Multiple RCTs and meta-analyses demonstrate that TRT improves sexual function and overall quality of life in hypogonadal patient subgroups, especially men with late-onset hypogonadism and erectile dysfunction, and that exercise can augment and prolong these benefits after discontinuation of TRT. Large cardiovascular safety trials and pooled RCT data indicate that, in men with hypogonadism and preexisting or high cardiovascular risk, TRT does not increase short- to medium-term risk of major adverse cardiovascular events, stroke, myocardial infarction, or all-cause mortality, and shows noninferiority to placebo for major cardiac outcomes when dosed to physiologic levels. [4] Recent meta-analyses of randomized trials and prospective cohorts suggest that when TRT is correctly applied to men with confirmed testosterone deficiency, it is not associated with increased cardiovascular risk and may even be associated with reduced major adverse cardiovascular events and improvements in cardiometabolic risk markers in certain high-risk subgroups. Overall, guideline-based use of TRT in symptomatic men with consistently low testosterone is supported by RCTs, meta-analyses, and major endocrine clinical practice guidelines as an evidence-based therapy to alleviate hypogonadal symptoms, improve sexual function and body composition, and maintain cardiovascular safety in the short to medium term when appropriately monitored. [1][2][3]
- Contradicts
- Evidence contradicts any blanket or unqualified claim that TRT is universally safe, risk-free, or beneficial for all men regardless of indication, dosing, or comorbidities. Meta-analyses of RCTs reveal conflicting findings regarding cardiovascular risk: some earlier pooled analyses reported an increased rate of cardiovascular-related events with testosterone therapy, while others found no clear effect (beneficial or harmful), highlighting uncertainty and the need for adequately powered long-term trials. [5][6][7][8] More recent systematic reviews emphasize that the overall quality of evidence for cardiovascular outcomes has often been low, with bias, inconsistency, and imprecision, and that existing trials were not primarily designed or powered to assess cardiovascular events or long-term mortality. RCT data also show that TRT can raise office blood pressure and is associated with hematocrit increases, with amplified blood pressure responses in men who are obese or have higher baseline red blood cell levels, which challenges any claim that TRT has no hemodynamic downsides. Safety reviews note increased rates of edema and modest reductions in HDL cholesterol in some populations, and guidelines stress that long-term safety beyond the short-to-medium term remains insufficiently characterized, particularly in older men with multiple comorbidities. [2] Therefore, strong claims that TRT prevents cardiovascular disease, is entirely free of cardiovascular or thromboembolic risk, or should be used broadly in men without clear hypogonadism are not supported; the evidence is mixed, context-dependent, and limited for long-term outcomes.
- Mainstream view
- The mainstream medical position is that testosterone replacement therapy is an established treatment for men with confirmed hypogonadism who have consistent biochemical testosterone deficiency and clinically significant symptoms, and should be used in accordance with major endocrine and urology guidelines. [2][5][6][7][8] Routine TRT in men with normal or age-related borderline testosterone levels, without clear symptoms and diagnostic confirmation, is not recommended. When TRT is prescribed, clinicians aim to restore testosterone to the physiological range and monitor hematocrit, lipids, blood pressure, prostate-related parameters, and cardiovascular status. [4] Current evidence indicates that appropriately dosed TRT improves sexual function, mood and energy in some men, and body composition, while short- to medium-term data do not show an increased rate of major cardiovascular events compared with placebo. However, due to prior conflicting meta-analyses, limitations of existing trials, and paucity of long-term safety data, mainstream guidelines consider cardiovascular safety not fully resolved and recommend caution and individualized risk–benefit assessment, especially in older men and those with significant cardiovascular disease. Overall, TRT is viewed as a useful, evidence-based therapy for properly selected hypogonadal men under medical supervision, not as a general longevity or performance drug for the broader male population. [1]
“TRT”
Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Functional Healthcare.
Functional Healthcare
- Supports
- No high-quality evidence in the provided index papers directly supports the vague claim 'Functional Healthcare. ' The only relevant support is indirect: major evidence-based clinical guidelines and updates show that standard medical care relies on condition-specific, evidence-based management rather than an established diagnostic or treatment category called 'functional healthcare'. [1][10][2]
- Contradicts
- The claim is too nonspecific to evaluate as a testable medical assertion, and the provided index papers do not define 'functional healthcare' as a recognized clinical entity or validated treatment framework. [10] The evidence listed consists of methodology guidance, disease-specific guidelines, and clinical trials on unrelated topics, so they do not substantiate a broad healthcare claim; this is a major evidence gap rather than confirmation. [2] In mainstream medical literature, the term is often used as a marketing or umbrella label, not as a standardized, evidence-based specialty with consistent diagnostic criteria or proven outcomes. [1]
- Mainstream view
- Mainstream medicine does not recognize 'Functional Healthcare' as a single, standardized, evidence-based medical category. [1] Care is generally organized around established diagnoses and guideline-based interventions, while any functional or integrative approach must still demonstrate safety and efficacy in condition-specific trials and guidelines. [2]
“Functional Healthcare”
Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure TRT.
TRT
- Supports
- High-quality evidence supports that properly indicated testosterone replacement therapy (TRT) in men with documented hypogonadism can improve several clinical outcomes, particularly sexual function, body composition, and aspects of quality of life. [5][7] Randomized controlled trials show that TRT increases lean body mass and reduces fat mass in hypogonadal men, including those with opioid-induced hypogonadism and aging men, with associated improvements in muscle function and oxidative stress profiles. [6][8] Multiple RCTs and meta-analyses demonstrate that TRT improves sexual function and overall quality of life in hypogonadal patient subgroups, especially men with late-onset hypogonadism and erectile dysfunction, and that exercise can augment and prolong these benefits after discontinuation of TRT. Large cardiovascular safety trials and pooled RCT data indicate that, in men with hypogonadism and preexisting or high cardiovascular risk, TRT does not increase short- to medium-term risk of major adverse cardiovascular events, stroke, myocardial infarction, or all-cause mortality, and shows noninferiority to placebo for major cardiac outcomes when dosed to physiologic levels. [4] Recent meta-analyses of randomized trials and prospective cohorts suggest that when TRT is correctly applied to men with confirmed testosterone deficiency, it is not associated with increased cardiovascular risk and may even be associated with reduced major adverse cardiovascular events and improvements in cardiometabolic risk markers in certain high-risk subgroups. Overall, guideline-based use of TRT in symptomatic men with consistently low testosterone is supported by RCTs, meta-analyses, and major endocrine clinical practice guidelines as an evidence-based therapy to alleviate hypogonadal symptoms, improve sexual function and body composition, and maintain cardiovascular safety in the short to medium term when appropriately monitored. [1][2][3]
- Contradicts
- Evidence contradicts any blanket or unqualified claim that TRT is universally safe, risk-free, or beneficial for all men regardless of indication, dosing, or comorbidities. Meta-analyses of RCTs reveal conflicting findings regarding cardiovascular risk: some earlier pooled analyses reported an increased rate of cardiovascular-related events with testosterone therapy, while others found no clear effect (beneficial or harmful), highlighting uncertainty and the need for adequately powered long-term trials. [5][6][7][8] More recent systematic reviews emphasize that the overall quality of evidence for cardiovascular outcomes has often been low, with bias, inconsistency, and imprecision, and that existing trials were not primarily designed or powered to assess cardiovascular events or long-term mortality. RCT data also show that TRT can raise office blood pressure and is associated with hematocrit increases, with amplified blood pressure responses in men who are obese or have higher baseline red blood cell levels, which challenges any claim that TRT has no hemodynamic downsides. Safety reviews note increased rates of edema and modest reductions in HDL cholesterol in some populations, and guidelines stress that long-term safety beyond the short-to-medium term remains insufficiently characterized, particularly in older men with multiple comorbidities. [2] Therefore, strong claims that TRT prevents cardiovascular disease, is entirely free of cardiovascular or thromboembolic risk, or should be used broadly in men without clear hypogonadism are not supported; the evidence is mixed, context-dependent, and limited for long-term outcomes.
- Mainstream view
- The mainstream medical position is that testosterone replacement therapy is an established treatment for men with confirmed hypogonadism who have consistent biochemical testosterone deficiency and clinically significant symptoms, and should be used in accordance with major endocrine and urology guidelines. [2][5][6][7][8] Routine TRT in men with normal or age-related borderline testosterone levels, without clear symptoms and diagnostic confirmation, is not recommended. When TRT is prescribed, clinicians aim to restore testosterone to the physiological range and monitor hematocrit, lipids, blood pressure, prostate-related parameters, and cardiovascular status. [4] Current evidence indicates that appropriately dosed TRT improves sexual function, mood and energy in some men, and body composition, while short- to medium-term data do not show an increased rate of major cardiovascular events compared with placebo. However, due to prior conflicting meta-analyses, limitations of existing trials, and paucity of long-term safety data, mainstream guidelines consider cardiovascular safety not fully resolved and recommend caution and individualized risk–benefit assessment, especially in older men and those with significant cardiovascular disease. Overall, TRT is viewed as a useful, evidence-based therapy for properly selected hypogonadal men under medical supervision, not as a general longevity or performance drug for the broader male population. [1]
“TRT”
Rule: Kansas chiropractic scope excludes prescription of medicine; K.S.A. 65-2871 et seq.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Softwave.
Softwave
- Supports
- No high-quality evidence in the provided index papers supports the claim, because the term Softwave is not addressed by the listed guidelines or trials. [2] The indexed papers concern hypertension management, clinical nutrition, bronchoscopy, protein quality, anesthesia, and INOCA registries rather than any intervention or product called Softwave . [1][3][4]
- Contradicts
- The claim is too vague to verify as written, and the provided evidence base does not match it. None of the index papers provide RCT, guideline, or meta-analytic support for a treatment, device, or medical benefit specifically called Softwave . In the absence of a defined claim, the evidence is effectively missing rather than supportive, and there is no basis in the supplied literature to conclude efficacy or safety. [1][2][3][4]
- Mainstream view
- Mainstream medical and scientific practice would require a specific, defined Softwave claim and supporting peer-reviewed clinical evidence before accepting it. [2] Based on the supplied index papers, there is no demonstrated guideline-level or trial-level evidence for Softwave, so the appropriate position is that the claim is unsubstantiated. [1][4] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Softwave”
Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Diagnosing/treating systemic/internal disease via 'Functional Healthcare', which is outside the musculoskeletal/spine scope of a DC. as within their scope of practice.
Diagnosing/treating systemic/internal disease via 'Functional Healthcare', which is outside the musculoskeletal/spine scope of a DC.
- Supports
- No high-quality evidence in the provided index papers directly supports the vague claim 'Functional Healthcare. ' The only relevant support is indirect: major evidence-based clinical guidelines and updates show that standard medical care relies on condition-specific, evidence-based management rather than an established diagnostic or treatment category called 'functional healthcare'. [1][10][2]
- Contradicts
- The claim is too nonspecific to evaluate as a testable medical assertion, and the provided index papers do not define 'functional healthcare' as a recognized clinical entity or validated treatment framework. [10] The evidence listed consists of methodology guidance, disease-specific guidelines, and clinical trials on unrelated topics, so they do not substantiate a broad healthcare claim; this is a major evidence gap rather than confirmation. [2] In mainstream medical literature, the term is often used as a marketing or umbrella label, not as a standardized, evidence-based specialty with consistent diagnostic criteria or proven outcomes. [1]
- Mainstream view
- Mainstream medicine does not recognize 'Functional Healthcare' as a single, standardized, evidence-based medical category. [1] Care is generally organized around established diagnoses and guideline-based interventions, while any functional or integrative approach must still demonstrate safety and efficacy in condition-specific trials and guidelines. [2]
“Functional Healthcare”
Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Using shockwave therapy (Softwave) for non-musculoskeletal conditions (aesthetics, urology, wound care), which exceeds standard chiropractic scope. as within their scope of practice.
Using shockwave therapy (Softwave) for non-musculoskeletal conditions (aesthetics, urology, wound care), which exceeds standard chiropractic scope.
- Supports
- No high-quality evidence in the provided index papers supports the claim, because the term Softwave is not addressed by the listed guidelines or trials. [2] The indexed papers concern hypertension management, clinical nutrition, bronchoscopy, protein quality, anesthesia, and INOCA registries rather than any intervention or product called Softwave . [1][3][4]
- Contradicts
- The claim is too vague to verify as written, and the provided evidence base does not match it. None of the index papers provide RCT, guideline, or meta-analytic support for a treatment, device, or medical benefit specifically called Softwave . In the absence of a defined claim, the evidence is effectively missing rather than supportive, and there is no basis in the supplied literature to conclude efficacy or safety. [1][2][3][4]
- Mainstream view
- Mainstream medical and scientific practice would require a specific, defined Softwave claim and supporting peer-reviewed clinical evidence before accepting it. [2] Based on the supplied index papers, there is no demonstrated guideline-level or trial-level evidence for Softwave, so the appropriate position is that the claim is unsubstantiated. [1][4] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Softwave”
Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.
Kirk Charles Johnson is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Softwave Shockwave Therapy for Urology/Aesthetics as within their scope of practice.
Softwave Shockwave Therapy for Urology/Aesthetics
- Supports
- No high-quality evidence in the provided index papers supports the claim, because the term Softwave is not addressed by the listed guidelines or trials. [2] The indexed papers concern hypertension management, clinical nutrition, bronchoscopy, protein quality, anesthesia, and INOCA registries rather than any intervention or product called Softwave . [1][3][4]
- Contradicts
- The claim is too vague to verify as written, and the provided evidence base does not match it. None of the index papers provide RCT, guideline, or meta-analytic support for a treatment, device, or medical benefit specifically called Softwave . In the absence of a defined claim, the evidence is effectively missing rather than supportive, and there is no basis in the supplied literature to conclude efficacy or safety. [1][2][3][4]
- Mainstream view
- Mainstream medical and scientific practice would require a specific, defined Softwave claim and supporting peer-reviewed clinical evidence before accepting it. [2] Based on the supplied index papers, there is no demonstrated guideline-level or trial-level evidence for Softwave, so the appropriate position is that the claim is unsubstantiated. [1][4] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Softwave”
Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq.
Manipulation
False Authority
source material
A chiropractor (DC) is framed as the leader of 'functional healthcare' and 'wellness' for all ages, implying broad medical authority that exceeds their state-board license limited to musculoskeletal/spine care. Likely motive: To attract patients seeking systemic disease management (e.g., hormones, gut issues) who would otherwise go to an MD/DO, by borrowing the authority of 'functional medicine'.
“Dr. Johnson is the Chiropractor to lead you on your path to wellness!”
Testimonial Overload
source material
Uses prestigious hospital names (Cleveland, Mayo) to validate a shockwave therapy (Softwave) for non-musculoskeletal uses (aesthetics, urology) without providing the actual evidence that DCs can perform these treatments. Likely motive: To create a false sense of scientific legitimacy for a therapy that is being marketed beyond its standard MSK scope to include systemic conditions.
Sales Funnel Motive
transcript · cited
Direct CTA to book an appointment for 'Functional Healthcare' and 'TRT' services that are likely outside the chiropractor's licensed scope, creating a revenue stream for unlicensed medical services. Likely motive: To monetize patients seeking hormone therapy and functional medicine by routing them into a cash-pay chiropractic clinic.
“Click here to Book an Appointment!”
Commerce & grift map
The grift pattern here is: frame a chiropractor as a 'functional medicine leader' -> attract patients seeking systemic disease management (hormones, gut issues) -> route them to cash-pay 'TRT' and 'Functional Healthcare' services that are outside the DC scope. The lack of disclosure and the use of prestigious hospital names (Cleveland, Mayo) to validate non-MSK claims creates a false sense of legitimacy for unlicensed medical services.
No FTC-style compensation disclosure
compensationDisclosures · scan
Host self-funnel around guest content
guestCollaboration · selfFunnel
Host routes viewers to their own consult/booking links around the guest segment.
Credentials & scope
Glossary: Chiropractor (“Dr.”)
Stated: Chiropractor
Verified against the federal provider registry: D.C. · Chiropractor · KS license 5021.
Kirk Johnson holds a real D.C. license but inflates it by advertising 'Functional Healthcare' and 'TRT' (Testosterone Replacement Therapy), which are strictly outside the scope of a chiropractor and require an MD/DO license.
- D.C., Doctor of Chiropractic
A state-licensed professional degree focused on musculoskeletal and nervous system conditions via spinal adjustment; not a medical doctor (MD) or osteopathic physician (DO).
State chiropractic boards typically limit scope to evaluation/treatment of musculoskeletal/nervous system conditions through spinal adjustment and authorized adjunctive therapies; excludes general internal medicine, prescription pharmacology, hormone therapy (TRT), or systemic disease management.
Permitted scope vs advertised
Kansas State Board of Healing Arts (Chiropractic) · Confidence: medium
Kansas chiropractors are licensed as practitioners of the healing arts, and the Kansas Chiropractic Practice Act defines chiropractic as the diagnosis and treatment of the human body by adjusting and manipulating the spinal column and other joints and tissues to correct neuro-musculoskeletal conditions and related effects. The statute expressly excludes prescribing medicine and performing surgery or obstetrics, so activities outside musculoskeletal/chiropractic care are not affirmatively authorized for a DC.[1][2]
What this license permits
- Spinal adjustment and manipulation
- Musculoskeletal evaluation and treatment
- Soft-tissue and rehabilitative care
- Headache care within musculoskeletal scope
8 of 8 advertised activities fall outside permitted scope.
| Advertised | Verdict |
|---|---|
| Prescribing Testosterone Replacement Therapy (TRT), a hormone/endocrine treatment that requires an MD/DO license, not a DC. Rule: Kansas chiropractic scope excludes prescription of medicine; Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq. Kansas chiropractic scope does not affirmatively authorize prescribing medicine, and TRT is a prescription hormone/endocrine treatment rather than chiropractic adjustment or manipulation. | Outside scope |
| TRT (Testosterone Replacement Therapy) Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq. TRT is a prescription hormone therapy and is not part of the Kansas chiropractic scope, which is limited to chiropractic diagnosis and treatment by spinal/joint adjustment and manipulation. | Outside scope |
| Listed service Functional Healthcare Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq. As advertised, 'Functional Healthcare' is a broad primary-care or systemic-health concept and is not affirmatively authorized in Kansas chiropractic scope unless tied to chiropractic musculoskeletal diagnosis and treatment. | Outside scope |
| Listed service TRT Rule: Kansas chiropractic scope excludes prescription of medicine; K.S.A. 65-2871 et seq. TRT is a hormone replacement prescription therapy, and Kansas chiropractic law does not authorize chiropractors to prescribe medication or provide endocrine treatment. | Outside scope |
| Listed service Softwave Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq. Softwave is shockwave therapy, which is not within the core Kansas chiropractic authorization unless specifically used as part of chiropractic treatment of musculoskeletal conditions; the advertisement here does not limit it to that scope. | Outside scope |
| Diagnosing/treating systemic/internal disease via 'Functional Healthcare', which is outside the musculoskeletal/spine scope of a DC. Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq. Kansas chiropractic scope is framed around neuro-musculoskeletal conditions, so diagnosing or treating systemic/internal disease under a 'Functional Healthcare' label is not affirmatively authorized. | Outside scope |
| Using shockwave therapy (Softwave) for non-musculoskeletal conditions (aesthetics, urology, wound care), which exceeds standard chiropractic scope. Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq. Kansas chiropractic authority does not affirmatively extend to aesthetic, urologic, or wound-care indications, so shockwave therapy for those non-musculoskeletal uses is outside scope. | Outside scope |
| Softwave Shockwave Therapy for Urology/Aesthetics Rule: Kansas Chiropractic Practice Act, K.S.A. 65-2871 et seq. Urology and aesthetics are not chiropractic musculoskeletal indications in Kansas, so this use of shockwave therapy is not affirmatively authorized for a DC. | Outside scope |
Sources: Kansas State Board of Healing Arts (official), Kansas Chiropractic Practice Act / Statutes and Regulations, Kansas Board of Healing Arts - Chiropractic Laws and Regulations (official), Kansas State Board of Healing Arts
Scope comparison mirror
Side-by-side view of the archived marketing homepage and what a Chiropractor scope permits near Foster Street Overland Park, KS. Open the mirror for the full comparison: archive on the left, permitted scope and licensed-care paths on the right.
Mirror generated 2026-07-17 18:57 UTC. The archive pane loads styles and images from the intake snapshot.
4 licensed-care paths linked for out-of-scope claims.
Validated associated properties
Surfaces tied to this Doc Bro by domain, branding, or funnel routing. Third-party platforms are labeled as routes, not as owned properties.
Analyzed
- OwnedOfficial site (drkirkjohnson.com)
Tip the jar
Report useful? Optional tips help keep scans, archives, and literature cross-checks running. They never change conclusions.
Submission oqq4dYeTV9jdexZai0NJS
Fight disinformation
Log a public thread where Kirk Charles Johnson is spreading nonsense, get a copy-paste reply with this report link.
Reply snippets
Before you buy the protocol: Dr. Trust Me Bro fact-checked Kirk Charles Johnson's claims with peer-reviewed sources, https://drtrustmebro.com/analyze/oqq4dYeTV9jdexZai0NJS. White-coat charisma isn't evidence.
Full DTMB scan on Kirk Charles Johnson: https://drtrustmebro.com/analyze/oqq4dYeTV9jdexZai0NJS
Drop these in YouTube comments, Reddit threads, and forums, link back to this scan, not vibes.
Recent mentions (this doc)
No conversation links logged yet. Be the first above.
Nudge the Doc Bro
We email a public contact address from their site so Kirk Charles Johnson can review this dossier and dispute anything we got wrong.
Know someone who can help?
If you think someone has firsthand information about Kirk Charles Johnson, send them an encouraging note. We email a short, respectful message with this report and clear instructions on how to write in, on the record or anonymously.
Whambulance
Challenge this scan or Wall of Fame entry for Kirk Charles Johnson. Public log, not legal arbitration.
Public challenge log
No posted Wall of Fame challenges linked yet.
Challenges are public on the Wall of Fame card. DTMB does not remove entries for hurt feelings, primary sources or copy corrections only.
File a challenge
Include in your email:
- Doc Bro ID: 5gMWbLgz9kRRrhtsHAAL4
- Wall entry: /influencer/5gMWbLgz9kRRrhtsHAAL4
- Analysis ID: oqq4dYeTV9jdexZai0NJS
- Source: https://www.drkirkjohnson.com
- Why this entry or scan should change
- Supporting links (one per line)
- Your business email (for verified disputes)
Verified challenges are posted publicly on the report. Public log, not legal arbitration.
Citations
Peer-reviewed and index sources cited in this report.
- [1] Guideline-Driven Management of Hypertension: An Evidence-Based Update.
- [2] ASPEN-FELANPE Clinical Guidelines.
- [3] ESPEN guideline: Clinical nutrition in inflammatory bowel disease.
- [4] When Is Parenteral Nutrition Appropriate?
- [5] Testosterone replacement therapy of opioid induced male hypogonadism improved body composition but not pain perception. A double-blinded, randomized and placebo-controlled trial.
- [6] Muscle function following testosterone replacement in men on opioid therapy for chronic non‐cancer pain: A randomized controlled trial
- [7] Depressive Syndromes in Men with Hypogonadism in the TRAVERSE Trial: Response to Testosterone Replacement Therapy.
- [8] Whole‐body oxidative stress reduction during testosterone therapy in aging men: A randomized placebo‐controlled trial
- [9] Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach.
- [10] AGA Clinical Practice Update on Medical Management of Colonic Diverticulitis: Expert Review.